Zura Bio Limited
NASDAQ:ZURABiotechnology
+$0.07 today
- Market cap
- $92.96M
- Beta
- 0.03
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.67
Volume 3.02M
Average 0.75M
ZURA Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Zura Bio LimitedNASDAQ: ZURA
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow grows, but more slowly than its trailing trend
Q1 FY2026 free cash flow of $18.94M (cash outflow) rose 70.4% year over year, behind the +112.3% change in trailing-twelve-month free cash flow. Sequentially, it fell 15.1% from the prior quarter. Over 3 fiscal years it compounded at +70.1% a year.
Context
- Free cash flow grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +70.4% toward the trailing-twelve-month pace of +112.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (64.93M) USD
- Year-over-year change
- -130.6%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (64.93M) | -130.6% |
| FY2024 | 2024-12-31 | (28.15M) | -22.1% |
| FY2023 | 2023-12-31 | (23.05M) | -74.6% |
| FY2022 | 2022-12-31 | (13.2M) | -1102.2% |
| FY2021 | 2021-12-31 | (1.1M) | — |
Free Cash Flow vs competitors
How ZURA compares with its peers on the latest reported figures
- ZURA's LTM Mar 2026 free cash flow of $72.75M is the 2nd largest of the 11 companies compared; the peer median is $55.16M.
- Its year-over-year change of +112.3% is the 2nd highest of 11, against a peer median of -16.9%.
- Over three fiscal years its annual growth of +70.1% compares with a peer median of -6.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $87.42M | -8.8% | — | 309.7% | |
ZURAZura Bio Limited | LTM Mar 2026 | $72.75M | +112.3% | +70.1% | — |
| LTM Mar 2026 | $66.98M | +12.6% | -12.8% | 483.3% | |
| LTM Mar 2026 | $64.63M | -24.7% | -18.0% | 28725.3% | |
| LTM Mar 2026 | $61.75M | +125.4% | +72.7% | — | |
| LTM Mar 2026 | $58.89M | -34.5% | — | 129.9% | |
| LTM Mar 2026 | $51.43M | -12.1% | +2.6% | — | |
| LTM Mar 2026 | $49.91M | -7.0% | +0.5% | — | |
| LTM Mar 2026 | $39.84M | -29.1% | -21.3% | 56.0% | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $39.73M | -21.7% | +23.1% | — |
| LTM Mar 2026 | $9.61M | -88.3% | -28.2% | 13.9% | |
| Peer median (excluding ZURA) | $55.16M | -16.9% | -6.2% | 219.8% | |
Competitors are the stored peer set for ZURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 8.42M | (27.33M) | (60.56M) | (52.4M) | (68.65M) |
| Depreciation & Amortization | 0 | 0 | 0 | 9K | 49K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 334K | 9.66M | 16.8M | 12.33M |
| Change in Working Capital | (235.6K) | 3.54M | 5.12M | 2.31M | (3.63M) |
| Accounts Receivables | 2.87K | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 288.29K | 0 | 4.21M | (2.16M) |
| Other Working Capital | (238.47K) | 3.25M | 5.12M | (1.91M) | (1.47M) |
| Other Non-Cash Items | (9.28M) | 22.26M | 30.74M | 5.21M | (4.91M) |
| Operating Cash Flow | (1.1M) | (1.2M) | (15.05M) | (28.08M) | (64.82M) |
| Capital Expenditures | (4) | (12M) | (8M) | (75K) | (113K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (139.38M) | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | (5M) | 0 |
| Investing Cash Flow | (139.38M) | (12M) | (8M) | (5.08M) | (113K) |
| Debt Repayment | (117.38K) | 7.6M | (10M) | 0 | 0 |
| Common Stock Issued | 140.82M | 0 | 116.41M | 60.76M | 5.2M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 505K | (2.83M) | 14.89M | 49.09M | (7.37M) |
| Financing Cash Flow | 141.21M | 14.77M | 121.29M | 109.84M | (2.16M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 729.22K | 1.57M | 98.24M | 76.69M | (67.09M) |
| Free Cash Flow | (1.1M) | (13.2M) | (23.05M) | (28.15M) | (64.93M) |
Zura Bio Limited
NASDAQ:ZURA
Intrinsic Alpha fair value
Locked
Current Price
$0.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.